Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11458412 | 0.81 | TSHR (0.45) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL7274798 | 0.81 | TSHR (0.50) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL28723924 | 0.79 | TSHR (0.44) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL9050409 | 0.79 | TSHR (0.34) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL6263483 | 0.79 | TSHR (0.42) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL27186888 | 0.79 | CYP1A2 (0.36) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL7820196 | 0.75 | HPRT1 (0.49) | TSHRACHEHSD17B10ALDH1A1TDP1 | |
| SCHEMBL3898476 | 0.70 | TSHR (0.58) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL261451 | 0.70 | TDP1 (0.45) | TSHRGPR35CYP3A4ACHEHSD17B10 | |
| SCHEMBL6047879 | 0.70 | MAPK1 (0.43) | ALDH1A1TDP1KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465814-B2 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2008-12-16 | — | — | US | claimed |
| CN-101277963-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | claimed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1910380-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | claimed |
| EP-1650200-A1 | SULFONATE COMPOUND AND FLUORESCENT PROBE USING THE SAME | Osaka Industrial Promotion Organization (JP) | 2006-04-26 | — | — | EP | claimed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | OSAKA INDUSTRIAL PROMOTION ORGANIZATION (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1650200-A1 | SULFONATE COMPOUND AND FLUORESCENT PROBE USING THE SAME | Osaka Industrial Promotion Organization (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-0322926-A2 | Assays utilizing improved chemiluminescent esters, thioesters and amides | LONDON DIAGNOSTICS, INC. (US) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105412-A1 | Sulfonate compound and fluorescent probe using the same | SLCO1B3, CBR3, SLCO2B1 | TSHR 2467/4885GPR35 3517/4885CYP3A4 276/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | TSHR 3288/4885GPR35 662/4885CYP3A4 3563/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | TSHR 2629/4885GPR35 4560/4885CYP3A4 26/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | TSHR 2980/4885GPR35 478/4885CYP3A4 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.